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ABSTRACT The vertebrate fibroblast growth factor receptor 1 (FGFR1) is alternatively spliced
generating multiple splice variants that are differentially expressed during embryo development
and in the adult body. The restricted expression patterns of FGFR1 isoforms, together with
differential expression and binding of specific ligands, leads to activation of common FGFR1 signal
transduction pathways, but may result in distinctively different biological responses as a result of
differences in cellular context. FGFR1 isoforms are also present in the nucleus in complex with
various fibroblast growth factors where they function to regulate transcription of target genes.
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Introduction
The vertebrate fibroblast growth factor receptor (FGFR) gene
family consists of four highly related genes, FGFR1, FGFR2,
FGFR3 and FGFR4, encoding polypeptides that are 55% to 72%
identical in their amino acid sequence (Johnson and Williams,
1993). Recently a new member of this family (FGFR5) was
identified in human and mouse (Kim et al., 2001; Sleeman et al.,
2001). FGFR5 is the most distantly related member of the FGFR
family, showing approximately 30% amino acid identity to other
FGFR proteins. FGF receptors are involved in many biological
processes during embryo development and homeostasis of adult
body tissues, and disruption of normal FGFR functions lead to
pathological conditions in humans. For example, mutations in the
FGFR genes are the cause of several human developmental
disorders characterized by skeletal abnormalities such as achon-
droplasia (i.e. dwarfism) (Muenke and Schell, 1995; Passos-
Bueno et al., 1999), and misregulation of FGFR mRNA splicing or
upregulation of FGFR expression may lead to cell transformation
and cancer (Yamaguchi et al., 1994; Valve et al., 2001).
Research in recent years has provided a wealth of new informa-
tion regarding the function of FGF receptors. In particular, the role
of FGFR1 during vertebrate embryo development and in the adult
body has been studied in detail. In this review, we will illuminate the
biological role of FGFR1 by describing its basic structure and
function as a signal transduction molecule regulating numerous
cellular processes in vertebrates. We will also focus on the poten-
tial role of nuclear FGFR1 as a regulator of transcription.
The General Structure of FGFR1
The general structure of FGFR1 and other FGF receptors is
highly conserved during evolution (Johnson and Williams, 1993).
A schematic diagram of the longest single-pass transmembrane
product encoded by the human FGFR1 gene is shown in Fig. 1.
The extracellular region consists of a signal peptide followed by
three immunoglobulin-like domains (Ig domains). Present be-
tween immunoglobulin-like domains II and III (IgII and IgIII) is the
acidic box domain, including 8 consecutive acidic residues, termed
the acidic box. A heparin-binding region important for interactions
with extracellular matrix (ECM) components and a cell adhesion
molecule (CAM) homology domain (CHD) are located down-
stream from the acidic box domain (Kan et al., 1991; Doherty and
Walsh, 1996). Continuous with the extracellular region is a trans-
membrane (TM) domain followed by an intracellular region. The
latter consists of a juxtamembrane domain next to the TM domain
and a tyrosine kinase domain, which is split by a 14 amino acid
long non-catalytic interkinase domain and followed by a short C-
terminal tail (Johnson and Williams, 1993).
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FGFR1 Splice Variants
The genomic organization of FGFR1 is still not fully characterised.
However, based on genomic comparison to other FGF receptor
genes it is likely that the human FGFR1 gene is comprised of 19
exons (Fig. 1; Johnson et al., 1991; Givol and Yayon, 1992; Cote
et al., 1997). Alternative splicing of FGFR1 transcripts generates a
diversity of isoforms, which are differentially expressed in cells and
tissues (Johnson and Williams, 1993). Figure 2 shows diagrams of
some of the reported FGFR1 splice variants. These are mainly of
human or murine origin, but isoforms isolated from frog and fish are
also represented. The protein structure of each isoform is deduced
from analysis of the cDNA sequence. Alternative sequence usage
can generate mRNA isoforms encoding receptors truncated in the
extracellular or intracellular region, lacking Ig-like domains, or
derived from different exons encoding variants of particular Ig-like
domains. For example, secreted receptor isoforms lacking the
kinase domain have been shown to result from alternative splicing
involving distinct sequences (Johnson et al., 1990; Eisemann et al.,
1991, Werner et al., 1992). One such variant is generated by
alternative splicing of mRNA from exon 3, which encodes IgI, to
normally intronic sequences from upstream of exon 4 (Fig. 2:
isoform 1). This mRNA encodes IgI followed by 32 unique amino
acids and a stop codon (Eisemann et al., 1991). Alternative splicing
of exon 7 sequences to three different downstream sequences
generates isoforms with a variable C-terminal half of IgIII (termed
FGFR1IIIa, FGFR1IIIb and FGFR1IIIc). The latter two isoforms,
produced by splicing exon 7 sequences to those of either exons 8
been found in the extracellular matrix and in blood where they may
function to regulate the biological activities of the FGFs during cell
proliferation and development (Hanneken, 2001; and see below).
Several groups have isolated cDNAs representing FGFR1 isoforms
with either 2 or 3 Ig domains, termed FGFR1β and FGFR1α,
respectively (Fig. 2: isoforms 2,3, 5-8; Dionne et al., 1990; Johnson
et al., 1990; Reid et al., 1990; Eisemann et al., 1991; Werner et al.,
1992; Johnson and Williams, 1993; Beer et al., 2000). The
physiological significance of inclusion or exclusion of IgI is still
largely unknown. However, it has been shown that a switch from
FGFRα to FGFRβ isoforms correlates with astrocyte malignancy
(Yamaguchi et al., 1994). This may be the result of changes in
ligand affinity between these two forms of FGFR1 receptor, as it
has been shown that FGFR1β isoforms exhibit a 10-fold higher
affinity for FGF1 and FGF2 than FGFR1α isoforms. This may lead
to a growth advantage for tumourigenic cells, resulting in the
development of a brain tumour (Shi et al., 1993; Wang et al., 1995).
FGFR1 is not only located at the cell surface but is also present in
the nucleus (Kilkenny and Hill, 1996). However, only the FGFRα
form has been found in the nucleus, suggesting that IgI is impor-
tant for nuclear targeting of this receptor (Prudovsky et al., 1996).
Subtle variations of structure have been found in the FGFR1α
and β isoforms. These are inclusions or exclusions of a RM
dipeptide downstream of the acidic box (Fig. 2: isoforms 2,3,7,8)
or of a VT dipeptide within the juxtamembrane domain (Fig. 2:
isoform 9). These isoforms are generated by alternative use of
slightly different splice donor sites at the exon/intron boundaries of
the exons encoding the acidic box and juxtamembrane regions
Fig. 1. Human FGFR1 protein and genomic structure. (A) The domain structure of
a 3 Ig domain FGFR1 protein is shown (modified from Johnson and Williams, 1993).
A type 1 C-tail is shown, which is found in isoforms that have kinase activity. Truncated,
kinase-deficient isoforms have been isolated with a different “type 2” C-tail. For
further details on domain structure see the text. (B) The first exon encodes a non-
translated promoter region and exons 8 and 9 encode the alternatively spliced C-
terminal half of IgIII. Domain sizes shown are not to scale.
or 9, have been shown to generate transmembrane pro-
teins with different ligand binding specificities (Fig. 2:
isoforms 5-12; and see below; Dionne et al., 1990; Johnson
et al., 1990; Reid et al., 1990; Eisemann et al., 1991; Hou
et al., 1991; Johnson and Williams, 1993; Gillespie et al.,
1995; Wang et al., 1996; Beer et al., 2000; Lopez and
Korch, 2000; C. Groth and M. Lardelli, unpublished results).
Splicing of mRNA from exon 7 to normally intronic se-
quences upstream of exons 8 and 9 generates another
truncated and secreted FGFR1 product (FGFR1IIIa), which
ends downstream of IgIII (Fig. 2: isoforms 2,3; Johnson et
al., 1990; Werner et al., 1992).
Little is known about the biological functions of truncated
soluble FGFR1 isoforms. The FGFR1IIIa isoform is ex-
pressed in postnatal and adult mouse tissues, and in
human cell lines (Duan et al., 1992; Werner et al., 1992) and
is present in the circulation (Hanneken, 2001). In the adult
murine retina the truncated FGFR1IIIa is differentially ex-
pressed compared to full-length FGFR1IIIc, suggesting a
specific role for this isoform in the retina (Guillonneau et al.,
1998). Soluble fibroblast growth factor receptors have also
been isolated that lack the transmembrane region (Givol
and Yayon, 1992). In our laboratory we have isolated from
zebrafish embryos a cDNA representing a FGFR1 variant
that lacks the second half of IgIII as well as the transmem-
brane domain, thus representing a putative soluble isoform
(Fig. 2: isoform4; C. Groth and M. Lardelli, unpublished
results). However, soluble FGFR1 receptors can also be
generated by proteolytic cleavage, resulting in ectodomain
shedding. The ectodomains from isoforms of FGFR1IIIb
and FGFR1IIIc with either two or three Ig domains have
A B
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(Eisemann et al., 1991; Gillespie et al., 1995). The VT dipeptide is
part of a protein kinase C (PKC) phosphorylation consensus
sequence within FGFR1 (Kennelly and Krebs, 1991). PKC-in-
duced FGFR1 activity is strictly regulated during embryo develop-
ment (Gillespie et al., 1995), and the relative expression levels of
VT-containing and VT-lacking FGFR1 isoforms have been found to
regulate mesoderm induction in Xenopus (Paterno et al., 2000).
Several kinase-deficient FGFR1 variants have been described.
For example, Wang et al. (1995) have isolated a cDNA which lacks
codons for 37 amino acids in the kinase 2 domain (Fig. 2: isoform
11). Hou et al. (1991) have characterized a transcript that, due to
the use of an alternative splice donor site in exon 14 of the FGFR1
gene, leads to a shift in the reading frame that truncates the second
heparan sulphate proteoglycans (HSPGs) and neural cell adhe-
sion molecules (CAMs). FGFR1 was originally identified as a high-
affinity receptor for fibroblast growth factors (FGF). In human and
mouse, 22 FGF genes have been identified (Ornitz and Itoh, 2001)
with diverse functions during embryo development and adult tissue
homeostasis, including the regulation of cell proliferation, differen-
tiation, wound healing, angiogenesis and malignant transforma-
tion as well as migration and neurite outgrowth (for reviews see
Szebenyi and Fallon, 1999; Powers et al., 2000). In vitro assays
with BaF3 cells show that FGFR1 isoforms have distinct FGF-
binding affinities and only bind FGF1 and FGF2 with high affinity
(Ornitz et al., 1996; Xu et al., 2000). The alternatively spliced C-
terminal half of the IgIII domain has been shown to play an essential
Fig. 2. FGFR1 isoform structures. Isoforms 1-4 are soluble receptors. 5-12 are transmem-
brane variants. Isoforms 11 and 12 are transmembrane proteins but are truncated in the
kinase domain and therefore represent kinase-deficient isoforms. Alternative sequences are
indicated by the colour code above the figures. The various isoforms were compiled from the
following sources: (1) Eisemann et al., 1991; (2) Werner et al., 1992; (3) Johnson et al., 1990;
Werner et al., 1992; (4) C. Groth and M. Lardelli, unpublished result; (5) Johnson and Williams,
1993; (6) Beer et al., 2000; (7) Dionne et al., 1990; Reid et al., 1990; Eisemann et al., 1991;
(8) Johnson et al., 1990; Reid et al., 1990; Eisemann et al., 1991; (9) Johnson et al., 1990; Reid
et al., 1990; Eisemann et al., 1991; Gillespie et al., 1995; (10) Lopez and Korc, 2000; (11) Wang
et al., 1996; (12) Hou et al., 1991.
kinase domain to 24 amino acid residues followed by
44 unique C-terminal residues (C-tail type 2) (Fig. 2:
isoform 12). The presence of kinase-deficient FGFR1
isoforms in cells that also express FGFR1 active
forms is thought to be a mechanism for regulating
the level of FGFR1 activity since kinase-deficient
and active forms can heterodimerize leading to non-
functional receptor dimers and down-regulation of
ligand-induced signal transduction (Shi et al., 1993).
Finally, an FGFR1 splice variant was isolated from
human placental tissue that is derived by skipping
exons 6 and 7 (encoding the C-terminal half of IgII
and N-terminal half of IgIII) and directly splicing
exons 5 and 9 together. This results in the genera-
tion of a product that can activate mitogenic signal-
ling without phosphorylating FRS2α (FGF receptor
substrate 2α) or phospholipase Cγ, key components
of two mitogenic signalling pathways (Fig 2: 10; and
see below).
The large number of different splice variants of
FGFR1 isolated from various vertebrate tissues
strongly suggests that FGFR1 isoforms have spe-
cific functions during development and in adult ho-
meostasis. However, the number of different FGFR1
isoforms, may to a certain degree, be exaggerated
for two reasons. First, many of the FGFR1 variants
have been identified as cDNAs isolated from
immortalised cell cultures. Thus, although they may
well be important for processes in pathological cell
states they may not be relevant for our understand-
ing of FGFR1 biology in the context of normal,
healthy tissues. Secondly, RT-PCR, the central tech-
nique used to identify FGFR1 isoforms, is highly
sensitive and may amplify cDNAs that are mere by-
products of normal FGFR1 RNA splicing and are
present at concentrations too low to have any physi-
ological effect.
FGFR1 Ligands
The generation of multiple FGFR1 isoforms by
alternative transcript splicing provides the basis for
differential binding of ligands to the receptor result-
ing in specific cellular responses. FGFR1 has been
found to interact with several different types of
ligand, including fibroblast growth factors (FGFs),
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role in determining specificities for FGF binding (Duan et al., 1992;
Werner et al., 1992; Ornitz et al., 1996; Beer et al., 2000), however
a number of other sequence segments in the IgI and IgII domains
and upstream of IgI may also significantly modulate ligand speci-
ficity (Chelliah et al., 1999). The actual FGF ligand-binding region
of FGFR1 has been located within IgII and IgIII (Zimmer et al.,
1993; Chellaiah et al., 1999).
It is becoming increasingly evident that the in vivo binding of
FGFs to FGFR1 is facilitated by HSPGs, which not only function as
co-receptors, but may play a prominent role in determining the
specificity of binding of FGFs to FGFR1. Thus, the results from in
vitro binding assays may not reflect the binding affinity of FGFs to
FGFR1 in vivo. This is illustrated by the developmental process of
patterning of the brain where FGF8 expression is highly restricted
at the midbrain-hindbrain boundary (MHB) and certain other re-
gions (Mason et al., 2000). However, FGFR1, which is the only
FGF receptor expressed at the MHB and so is the most likely
candidate for a cognate FGF8 receptor, does not bind FGF8 in in
vitro assays (MacArthur et al., 1995; Ornitz et al., 1996; Blunt et al.,
1997), indicating that endogenous HSPGs may alter the binding
affinity of FGF8 for FGFR1, leading to signal transduction in vivo.
HSPGs can be divided into cell surface and extracellular matrix
(ECM) proteins (for reviews see Iozzo, 1998; Bernfield et al.,
1999). HSPG chains are linear polysaccharides made up of
repeating disaccharide unit backbones, which are synthesised and
attached to the HSPG core protein in the Golgi-complex. They are
then modified further in several steps, including the addition of
sulphate groups at various positions. This provides the basis for
generation of structurally different HSPGs, contributing to the
generation of differential binding affinities of FGFR1 for FGFs
(Perrimon and Bernfield, 2000). For example, it has been shown
that in the neural precursor cells of the developing murine nervous
system, the expression of specific HSPGs is highly regulated,
leading to a shift in affinity from FGF2 to FGF1. This may have a
significant effect on FGFR signalling at a critical phase during
murine brain development where the differentiation of hundreds of
different subclasses of neurons and glia is initiated (Nurcombe et
al., 1993). HSPGs have been shown to be involved in a variety of
biological processes during embryo development and in the adult
organism, including cell proliferation, differentiation, wound heal-
ing, angiogenesis, regulation of blood coagulation, cell adhesion
and malignant transformation (for review see Tumova et al., 2000).
It is now well established that specific FGFs facilitated by
HSPGs activate FGFR1 by inducing dimerization. Based on this,
a general model has been proposed where two FGF molecules
interact with one HSPG to facilitate and stabilise the binding of the
FGFs to two FGFR1 molecules, leading to activation of the tyrosine
kinase domain (Fig. 3; Plotnikov et al., 1999).
FGFR1 has also been implicated in interactions with the neural
cell adhesion molecules (CAMs) such as L1, NCAM and N-
cadherin that play an important role during the development of the
nervous system by mediating cell-cell interactions necessary for
cell migration, neurite outgrowth and other physiological pro-
cesses. CAMs have also been shown to be involved in the
regeneration and synaptic plasticity of the neurons in the adult
nervous system (Doherty and Walsh, 1996; Benson et al., 2000).
Although no direct evidence has been established for the binding
of FGFR1 to CAMs, several studies, using inhibitors against
components of the PLCγ cascade and FGFR1 have demonstrated,
that in the presence of these inhibitors both CAM- and FGF-
stimulated neurite outgrowth could be blocked. This suggests that
FGFs and CAMs utilize a common PLCγ pathway via FGFR1 to
initiate the neurite outgrowth response (Doherty and Walsh, 1996).
Furthermore, a putative evolutionarily conserved CAM binding
sequence (CAM homology domain, CHD) has been identified in
FGFR1 and thought to interact directly with a CHD binding motif in
the CAMs. Sharing of common binding motifs may lead to cis and
trans homophilic/heterophilic binding between CAMs and FGFR1
and subsequent clustering of CAM/FGFR1 complexes followed by
activation of FGFR1 and signal transduction (Fig. 3; Doherty and
Walsh, 1996). Co-clustering of N-cadherin and FGFR1 has re-
cently been demonstrated, lending support for this model (Utton et
al., 2001). It is worth pointing out, that even if both CAMs and FGFs
interact with FGFR1, the cellular responses may be different, due
to possible differences in the way the ligands interact and mediate
dimerization and activation of FGFR1 (Doherty and Walsh, 1996).
FGFR1 Signal Transduction
After binding of the ligand to FGFR1, the signal must be
transmitted across the plasma membrane and generate an appro-
priate biological response in the cell. Initiation of signal transduc-
tion is believed to be achieved by conformational changes in the
receptor upon ligand binding, leading to dimerization and subse-
A B
Fig. 3. Putative FGF- and CAM-mediated FGFR1 activation complexes.
(A) HSPG facilitated binding of FGFs to FGFR1 leads to receptor activation.
(B) The receptor may also be activated through interactions with CAM
molecules.
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quent activation of FGFR1 by autophosphorylation of the intracel-
lular domain (McKeehan et al., 1998). Seven tyrosine residues
have been identified as potential substrates for phosphorylation
and are important for kinase activity and receptor signalling
(Mohammadi et al., 1996). Activation of the receptor allows pro-
teins containing Src homology (SH2) or phosphotyrosine binding
(PTB) domains to bind to sequence recognition motifs in FGFR1,
resulting in phosphorylation and activation of these proteins (Pawson
et al., 1993; Forman-Kay and Pawson, 1999; Dhalluin et al., 2000).
For example, phosphorylated FGFR1 tyrosine 766 is a high-affinity
binding site for phospholipase Cγ (PLCγ) (Mohammadi et al.,
1992). Activated PLCγ  can hydrolyse phospatidylinositol-4,5-
diphosphate (PIP2) to inositol-1,4,5-triphosphate (IP3) and
diacylglycerol (DAG). IP3 induces Ca
2+ release from intracellular
stores, whereas DAG is a PKC activator. Both CAM- and FGF2-
stimulated neurite outgrowth has been suggested to rely on the
same PLCγ cascade, involving conversion of DAG to arachidonic
acid (AA) by DAG lipase and an AA-induced increase in calcium
influx into neurons via calcium channels leading to activation of
calcium-dependent proteins (Fig. 4; Doherty and Walsh, 1996).
The Ras/mitogen activated protein kinase (MAPK) pathway is
another important signalling cascade utilised by FGF-mediated
activation of FGFR1. The adaptor protein FRS2α has been shown
to link FGFR1 activation to this cascade. The PTB domain of
FRS2α interacts with the juxtamembrane region of FGFR1 (Ong et
al., 2000), and following tyrosine phosphorylation by FGFR1 it
binds the adaptor protein Grb2 (Growth factor receptor-bound
protein 2), which can form a complex with Sos (Son of sevenless),
a guanine nucleotide exchange factor. The proximity of the Grb2/
Sos complex to the cell surface allows Sos to activate the G protein
Ras by GDP for GTP exchange, leading to activation of the Ras/
MAPK signalling pathway (Fig. 4; Kouhara et al., 1997; Ong et al.,
2000; Hadari et al., 2001). Activated MAPK can phosphorylate
cellular proteins (e.g. Sos), and also migrate into the nucleus and
activate transcription factors by phosphorylation (e.g. JUN and
FOS) (for a review see Karin and Hunter, 1995). Several groups
have demonstrated the importance of FRS2α in FGFR1-mediated
signal transduction in various biological processes such as cell
proliferation, migration and embryo development (Ong et al., 2000;
Hadari et al., 2001). It is interesting that the FRS2α binding site
overlaps with a phosphorylation consensus sequence, which al-
lows for PKC regulation of FGFR1 signalling (see above; Gillespie
et al., 1995). An alanine substitution for valine in the VT dipeptide
significantly diminishes FRS2α binding to FGFR1 and phosphory-
lation of FRS2α by FGFR1, leading to a reduction in MAPK activity
(Ong et al., 2000). In addition, FRS2α-deficient mice die early
during embryo development (Hadari et al., 2001). Taken together
these findings suggest that FRS2α and PKC interactions with
FGFR1 play an important role during early vertebrate develop-
ment.
A more detailed understanding of the role of the FGFR1 path-
way in certain aspects of brain development is slowly emerging due
to recent work by Faux et al. (2001) who provide evidence of cross-
talk between the FGFR1 signalling pathway and the Notch signal-
ling pathway (another important developmental signalling system).
It has long been known that stimulation of FGFR1 signalling by
FGF1 or FGF2 inhibits neuronal differentiation (Murphy et al.,
1990). Cell-cell interactions mediated by the Notch signalling
pathway are essential for regulation of neuron differentiation by
maintaining precursor cells in an undifferentiated and proliferative
state and, thus, inhibiting neurogenesis (Lewis, 1998). However,
the downstream developmental cascade responsible for transduc-
tion of the FGF signal that inhibits neurogenesis remained elusive.
The neurons and glia, which make up the intricate neuronal
network of the nervous system, originate from neuroepithelial
precursor (NEP) cells found within the neural tube (Faux et al.,
2001). A connection between FGFR1 and Notch signalling was
established using murine forebrain NEP cells in vitro to demon-
strate that FGF1- and FGF2-mediated FGFR1 signalling regulates
the expression of Notch and Delta, key components of the Notch
pathway, which subsequently leads to inhibition of neurogenesis
(Faux et al., 2001).
The Importance of Nuclear FGFR1
FGFR1 is generally recognized as a protein of the plasma
membrane, transmitting signals to the nucleus via the Ras/
MAPK pathway (Karin and Hunter, 1995). However, recent find-
ings suggest that FGFR1 may function after internalisation by
Fig. 4. Intracellular signalling pathways activated by FGFR1. Two
major signal transduction pathways, Ras/MAPK and PLCγ, are shown. The
positions of the potential phosphotyrosine sites in human FGFR1 are
indicated. FGFR1 signalling may activate the Notch signalling pathway via
the Ras/MAPK cascade or possibly, via a direct interaction of nuclear FGF/
FGFR1 complexes.
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receptor-mediated endocytosis, which is the principal mechanism
for inactivation of the receptor (Sorokin et al., 1994; Reilly and
Maher, 2001). A fraction of the internalised FGFR1 is targeted to
the nucleus as FGF/FGFR1 complexes where it may be involved
in the induction of cell proliferation and differentiation (Karesztes
and Boonstra, 1999). Nuclear translocation of FGF2/FGFR1 com-
plexes is mediated through interaction of FGFR1 with importin β,
a critical component of multiple nuclear import pathways (Reilly
and Maher, 2001). Nuclear FGFR1 shows kinase activity (Maher,
1996) and has been implicated in regulation of the cell cycle by
inducing the expression of c-Jun, which subsequently leads to the
induction of cyclin D1 expression (the principal G1-phase cyclin,
followed by cell proliferation) (Reilly and Maher, 2001). It is tempt-
ing to speculate that the interaction between the FGFR1 and Notch
signalling pathways demonstrated by Faux et al. (2001) could be
accomplished by nuclear FGF/FGFR1 complexes regulating Notch
and Delta gene expression.
The Role of FGFR1 during Development
Vertebrates share a common evolutionary origin, which can be
dated back more than 500 million years (Holland and Chen, 2001).
Comparative analysis of FGFR1 expression patterns between verte-
brates may help to gain insights into the evolution of vertebrate
FGFR1 function during development. Expression analyses of FGFR1
in different vertebrates demonstrate a high degree of evolutionary
conservation during vertebrate embryo development. For example,
FGFR1 is expressed during the period of mesoderm induction in
chick, mouse and frog (Xenopus) (Yamaguchi et al., 1992; Golub et
al., 2000; Walshe and Mason, 2000). Embryos from both FGFR1-
deficient mice and from Xenopus overexpressing a dominant nega-
tive FGFR1 exhibit defects in mesoderm formation, suggesting an
important role for FGFR1 in this developmental process (Amaya et
al., 1991; Yamaguchi et al., 1994). FGFR1 is ubiquitously expressed
during development of the brain in chick, mouse and Xenopus, with
high levels of expression reported in the forebrain and midbrain-
hindbrain boundary (MHB) in mouse and Xenopus (Yamaguchi et al.,
1992; Golub et al., 2000; Walshe and Mason, 2000). Interestingly,
chick embryos do not show any distinct high level FGFR1 expression
domains during early neural development while in Medaka fish
(Oryzias latipes) FGFR1 expression is excluded from the anterior
region of the developing brain (Carl and Wittbrodt, 1999; Walshe and
Mason, 2000). We have recently isolated the zebrafish (Danio rerio)
fgfr1 gene (C. Groth and M. Lardelli, unpublished results). In contrast
to observations in Medaka, the expression pattern of zebrafish fgfr1
is similar to that of Xenopus, showing ubiquitous expression during
early neural development with high level expression domains in the
forebrain and MHB. The MHB, also termed the isthmus organizer,
produces signalling molecules such as FGF8 that induce the speci-
fication and patterning of adjacent brain structures (Reifers et al.,
1998). FGFR1 is expressed at the MHB in all of the above vertebrates
except Medaka. In chick and mouse, FGFR1 is the only known FGF
receptor expressed at the MHB (Wilke et al., 1997). Furthermore the
elevated FGFR1 expression in this region in zebrafish and Xenopus
suggests that FGFR1 is the receptor for FGF8-mediated signal
transduction at the MHB in these vertebrates. In Medaka neither
FGFR1 nor any of the other three highly related FGFR genes
(FGFR2, FGFR3 and FGFR4) show expression overlapping with
that of FGF8 at the MHB. Thus, FGF8 may transduce its signal at the
MHB via a yet unidentified receptor in this species. The expression
patterns of FGFR1 during somite formation share many similar
features among amphibians, fish, birds and mammals (Yamaguchi
et al., 1992; Carl and Wittbrodt, 1999; Golub et al., 2000; Walshe and
Mason, 2000; C. Groth and M. Lardelli, unpublished observations).
FGFR1 is expressed in the presomitic mesoderm just posterior to
newly formed somites and in the first 2-5 somites but is absent from
older somites. A more detailed analysis of FGFR1 expression has
been performed in mouse and zebrafish, showing that the expres-
sion is restricted to the anterior half of the somites, whereas in
Medaka FGFR1 expression is found in the lateral areas of somites
(Yamaguchi et al., 1992; Carl and Wittbrodt, 1999; C. Groth and M.
Lardelli, unpublished observations).
In situ hybridisation studies to localise FGFR1 expression
during embryo development and in the adult body have mainly
been performed using probes covering the kinase domain. Thus,
these analyses show the cumulative expression of all transcripts
not encoding intracellularly-truncated receptors. However, the few
studies based on Northern blots, RNase protection assays and
immunological staining that have included isoform-specific probes
show that the isoforms are differentially expressed (Reid et al.,
1990; Werner et al., 1992; Guillonneau et al., 1998; Beer et al.,
2000). The lack of detailed knowledge about the expression
patterns of the various FGFR1 splice forms is surprising consider-
ing the large number of isoforms that have been isolated (Fig. 2),
indicating that a driving force in the evolution of FGFR1 function
has been the generation of isoforms to perform specific functional
roles during embryo development and adult homeostasis. In the
adult body, the FGFR1IIIc isoforms are preferentially expressed
compared to FGFR1IIb isoforms (Werner et al., 1992; Beer et al.,
2000). In addition, mice with targeted deletions of exon 8 or 9
(required for isoforms FGFR1IIIb or IIIc, respectively) have been
generated. The developmental defects of FGFR1IIIc-isoform defi-
ciency were severe and these mouse embryos died early during
development while mice lacking FGFR1IIIb isoforms were viable
and fertile with few developmental abnormalities. This indicates
that the FGFR1IIIc isoforms are critical for embryo development,
whereas splice variants encompassing the FGFR1IIIb specific
sequence apparently are not (Partanen et al., 1998). Also, targeted
disruption in mice of exon 3 that encodes IgI, a domain found
exclusively in FGFR1α isoforms, has demonstrated that these
splice variants play a pivotal role during mesoderm induction and
other early developmental processes, but may not be essential
during somitogenesis (Xu et al., 1999).
Conclusions
Since the isolation of the first complete cDNA of a vertebrate
FGF receptor 1 more than 10 years ago a great variety of FGFR1
splice variants have been isolated. However, only a few of these
have received more than initial characterisation. A major challenge
in the coming years will be to establish the spatio-temporal expres-
sion patterns of the various isoforms during embryo development
and to analyse the functional significance of each of the FGFR1
variants in a developmental context as well as in adult tissues
homeostasis. Based on recent years studies, a conceptual under-
standing is slowly emerging of how FGFR1 signalling can result in
specific biological responses of particular cell populations. In order
to get a restricted and highly local response only the cells intended
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to respond to signals in their environment must be able to be
transmit these signals across the cell membrane and initiate signal
transduction events, whereas other cells in the local environment
must remain unresponsive. This is likely to be achieved by the
combined differential expression of FGFR1 isoforms, FGFs and
HSPGs, leading to highly restricted activation of FGFR1 signalling
only in cells with the right combination of ligand and receptor
molecules. The biological outcome of signals generated at the cell
surface in response to ligand induced FGFR1 activation is strongly
dependent on the cellular context. For example, during early
embryo development, FGFR1 plays an important role in control of
cell migration, a process crucial for mesodermal patterning and
gastrulation, while the activation of FGFR1 signalling in fibroblasts
promotes cell proliferation (Schlessinger, 2000). This suggests
that common intracellular signalling pathways activated by FGFR1
are able to interact with cell-type specific effector proteins and
transcription factors, leading to a specific biological response. The
characterisation of components of the various FGFR1 activated
signalling pathways and their regulation is progressing rapidly.
However, the role of nuclear FGFR1 in regulation of transcription
is less well studied and deserves more attention in the future.
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